Hexima Limited.
HXL.ASXHealth Care
Research and development of plant-derived proteins and peptides for applications as human therapeutics.
Market Data
$0.013
0.0%-$1.00
-100000.0x
$-0.006
0.00%
-0.6%
Latest Earnings
Appendix 4D & Interim Financial Report
27 February 2026
Hexima Limited reported a loss of $128,570 for HY2025, down 68% from $406,473 in the prior year, primarily due to the absence of significant due diligence expenses that occurred in the prior period. The company remains suspended from ASX trading with no operating activities, managing only residual intellectual property interests (a 2% royalty in onychomycosis IP and a Corteva licence agreement). Management is evaluating capital management alternatives including a potential $1m return of capital to shareholders and considering delisting, with cash holdings of $1.4m as of 31 December 2025. Key points: Net loss reduced 68% year-on-year to $128,570, primarily due to the absence of prior-year due diligence expenses ($242,143); Cash burn improved significantly with net cash outflows of $132,542 vs $584,974 in pcp, reflecting successful cost management; Cash position of $1.4m sufficient to cover near-term compliance and listing costs
Recent Announcements
Appendix 4D & Interim Financial Report
Hexima Limited reported a loss of $128,570 for HY2025, down 68% from $406,473 in the prior year, primarily due to the absence of significant due diligence expenses that occurred in the prior period. The company remains suspended from ASX trading with no operating activities, managing only residual intellectual property interests (a 2% royalty in onychomycosis IP and a Corteva licence agreement). Management is evaluating capital management alternatives including a potential $1m return of capital to shareholders and considering delisting, with cash holdings of $1.4m as of 31 December 2025. Key points: Net loss reduced 68% year-on-year to $128,570, primarily due to the absence of prior-year due diligence expenses ($242,143); Cash burn improved significantly with net cash outflows of $132,542 vs $584,974 in pcp, reflecting successful cost management; Cash position of $1.4m sufficient to cover near-term compliance and listing costs
Get real-time alerts for HXL
Receive AI-powered earnings summaries and instant notifications when Hexima Limited. releases results.
Register Free